3396.HK

Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing

Retrieved on: 
星期五, 十二月 9, 2022

HONG KONG, Dec 9, 2022 - (ACN Newswire) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital.

Key Points: 
  • HONG KONG, Dec 9, 2022 - (ACN Newswire) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital.
  • Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain.
  • GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF.
  • The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences.

Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq

Retrieved on: 
星期日, 十一月 13, 2022

HONG KONG, Nov 13, 2022 - (ACN Newswire) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States.

Key Points: 
  • HONG KONG, Nov 13, 2022 - (ACN Newswire) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States.
  • Founded in 2013, Atour is a leading hospitality and lifestyle company in China with a distinct portfolio of lifestyle hotel brands, such as A.T. HOUSE, Atour S, ZHOTEL, Atour Hotel, Atour X and Atour Light, as well as scenario-based retail brands, including Atour Market.
  • As an important institutional investor and close partner of Atour, Legend Capital led the investment in Atour in 2016, and continued to make additional investments in Atour's subsequent financing rounds in 2017 and 2021.
  • Legend Capital said: " The past nine years have witnessed Atour's continuous development since its first hotel opening in 2013.

Led by Legend Capital, PureFDA Secures Over CNY100 million in the Series B Round

Retrieved on: 
星期四, 十一月 10, 2022

HONG KONG, Nov 10, 2022 - (ACN Newswire) - Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital.

Key Points: 
  • HONG KONG, Nov 10, 2022 - (ACN Newswire) - Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital.
  • The company's service network has spread to 10 countries and regions worldwide, including the United States, Germany, Italy, Spain, Switzerland and Poland.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.